Aim: Portopulmonary hypertension is a serious complication of portal hypertension that can lead to right heart failure and death. To our knowledge, an association between portopulmonary hypertension and prior splenectomy has not been described previously. The goals of this study were to describe the frequency of splenectomy in portopulmonary hypertension and compare selected parameters between portopulmonary hypertension subgroups.
INTRODUCTION

P
ORTOPULMONARY HYPERTENSION (POPH) is a subcategory of pulmonary artery hypertension that is important to diagnose in the setting of portal hypertension, as it can lead to devastating consequences such as right heart failure and death. 1, 2 Epidemiologic studies suggest that POPH occurs in 4.5-8.5% of patients that are eligible for liver transplantation.
1,2 The Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL registry) reports a 5.3% POPH prevalence in all patients with pulmonary arterial hypertension and a POPH 5-year survival of 40%. [3] [4] [5] Portopulmonary hypertension is classified under World Health Organization (WHO) Group 1 pulmonary hypertension, a grouping based on similar pulmonary vascular pathologies. Portal hypertension, a necessary pre-existing condition for the POPH diagnosis, is associated with several autoimmune disorders such as autoimmune hepatitis-related cirrhosis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). 6, 7 Factors specifically associated with POPH include female sex and AIH. 4, 8 Of potential interest is that splenectomy has been associated with different types of pulmonary hypertension (WHO Groups 1, 4, and 5), yet is a therapy that has been used to treat complications of portal hypertension. 6, 7, [9] [10] [11] [12] To our knowledge, the relationship between splenectomy and POPH has not been described to date. The goals of this observational study were to describe the frequency of splenectomy in POPH as well as possible relationships among POPH-associated liver diseases. We hypothesized that POPH patients with prior history of splenectomy would have more severe and sooner onset of POPH, as measured by echocardiography and right heart catheterization (RHC) parameters. Brief descriptions of POPH patients who underwent splenectomy are summarized. Individual patient consent was not required as this study was a retrospective chart review with no direct patient contact and no identifying data were used. The study was approved by the Mayo Clinic Institutional Review Board.
METHODS
A
This study was a retrospective analysis of consecutive patients who were diagnosed with POPH per RHC criteria between 1 January 1988 and 30 June 2015 and entered into the database.
The diagnosis of POPH fulfilled the following criteria: (i) portal hypertension (ascites, varices, and splenomegaly); (ii) mean pulmonary artery pressure (MPAP) > 25 mmHg; (iii) pulmonary artery wedge pressure (PAWP) <15 mmHg; and (iv) pulmonary vascular resistance (PVR) > 240 dyne*s*cm
À5
. Portopulmonary hypertension was considered to exist if the above criteria were met in addition to transpulmonary gradient (MPAP-PAWP) >12 mmHg, as well as lack of evidence or suspicion for alternative pulmonary hypertension etiologies. The majority of patients were evaluated with ventilation/perfusion scan, chest computed tomography angiography, or direct pulmonary angiography and determined not to have underlying chronic thromboembolic pulmonary hypertension (CTEPH). Additionally, most patients were evaluated through history as well as laboratory testing and determined not to have underlying connective tissue diseases or hematologic disorders.
We compared the age, sex, right ventricular systolic pressure (RVSP) estimated by transthoracic echocardiography (TTE), and specific RHC measurements including MPAP, PAWP, transpulmonary gradient, cardiac output, and PVR among subgroups of POPH patients with splenectomy as well as selected liver diseases that were autoimmune in nature (autoimmune hepatitis [AIH] , primary biliary cirrhosis [PBC] , and primary sclerosing cholangitis [PSC] ). These autoimmune disorders were selected due to the previous relationship described between POPH and autoimmune liver disease. 8 The TTE and RHC measurements/calculations were obtained at the time of POPH diagnosis.
Statistical analyses were undertaken using ANOVA testing and T-tests as appropriate. JMP 10 software (SAS institute, Cary, NC, USA) was used for all analyses.
RESULTS
A
TOTAL OF 141 POPH patients comprised the study cohort. There were 8 (6%) POPH patients with a history of splenectomy, 27 (19%) patients had autoimmune liver disease (AIH/PBC/PSC), and 5 (4%) patients had both conditions. The percentage of patients in the AIH/PBC/PSC group with a splenectomy was 18.5% (5/ 27). The percentage of patients with history of splenectomy that had autoimmune liver disease was 62.5% (5/8).
The RVSP was significantly higher (mean, 103.7 mmHg; median, 118; interquartile range, 51) in the isolated splenectomy group. Splenectomy was not associated with significantly different pulmonary hemodynamics (MPAP and PVR). Further details regarding specific measurements/calculations are found in Table 1 .
Patients with AIH/PBC/PSC, regardless of splenectomy history, were mainly female (85%). The average age of POPH onset in the isolated splenectomy group (47 years) was not significantly different than patients with isolated AIH/PBC/PSC (54 years). The time interval between splenectomy and development of POPH ranged from 8.8 to 43 years. Of the 8 splenectomy patients, 2 had underlying PSC, 2 had AIH, 1 with PBC, and 3 without underlying autoimmune disease. Further splenectomy patient details are found in Table 2 .
DISCUSSION
T HE DATA DESCRIBED herein is the first analysis to address the relationship between splenectomy and the development of a specific subgroup of pulmonary artery hypertension, namely POPH.
The prevalence of patients with splenectomy (6%) was similar to previous studies looking at splenectomy prevalence in idiopathic pulmonary arterial hypertension (IPAH) (WHO Group 1) and CTEPH (WHO Group 4). 7 Splenectomized patients had a similar degree of POPH severity at time of RHC diagnosis. Despite the majority of splenectomized patients developing both portal hypertension and having their splenectomy in childhood or early adulthood, the age at POPH diagnosis was not significantly different from other POPH patients.
Prior to our study, it seemed reasonable to speculate that, if splenectomy can lead to pulmonary hypertension, and portal hypertension can lead to POPH, that patients with splenectomy and portal hypertension would be at higher risk of developing more severe and sooner onset POPH. However, the only notable difference was that the isolated splenectomy group had a significantly higher RVSP measured by TTE.
The RVSP being significantly higher in the splenectomy group has potential clinical implications relating to POPH screening in patients with liver disease. There may be an opportunity to diagnose POPH sooner with earlier TTE screening. Clinicians should consider screening for POPH in patients with autoimmune liver disease and in those who have had a prior history of splenectomy.
Splenectomized POPH patients
The reasons for splenectomy were variable, as listed in Table 2 . The majority of splenectomized patients, except the patient with congenital asplenia, developed portal hypertension prior to splenectomy. Most developed portal hypertension and had splenectomies during childhood or early adulthood. The etiology for portal hypertension in the majority of these patients was underlying liver dysfunction. There were two exceptions to this: one patient had portal hypertension secondary to portal vein thrombosis related to protein C/S deficiency (CTEPH negative by chest computed tomography angiography), and the other had an umbilical vein infection leading to portal hypertension. The patient with a history of umbilical vein infection also happened to develop alcoholic liver disease years later.
REVIEW OF PUBLISHED WORK
Splenectomy and subsequent pulmonary hypertension T HE PREVALENCE OF splenectomy in the general population is estimated to be 0.4%, whereas with IPAH and CTEPH it is much higher, ranging from 2.5 to 11.5% and 5.5 to 9%, respectively. [13] [14] [15] [16] The increased prevalence of splenectomy in our POPH cohort (6%) was similar to previous IPAH and CTEPH studies (see Table 3 ). [13] [14] [15] [16] [17] [18] Patients with IPAH develop thrombosis in situ, whereas those with CTEPH develop clots that embolize and obstruct larger pulmonary vessels. 17 Patients who have undergone splenectomies appear to have both types of lesions; however, a recent review article suggests that the spectrum of distal CTEPH and IPAH disease may be more closely related to CTEPH. 17, 18 When Kimmig and Palevsky 18 examined studies correlating an increased prevalence of splenectomy in patients with CTEPH and IPAH, they found that some of the clinically diagnosed IPAH patients may have, in fact, had distal CTEPH. This was exemplified by a study that found precapillary thrombotic lesions in explanted lung vasculature in some of the IPAH splenectomy patients. 13, 18 Only a small fraction of CTEPH patients have a history of splenectomy, but splenectomy patients have an odds ratio as high as 18 for developing CTEPH. 16, 18 The tendency towards thrombosis in patients without a spleen is related to thrombocytosis, increased circulating damaged red blood cells, procoagulants, microparticles, and cellular debris. 17, 18 Microparticles have exposed peptidyl-serine which normally signals consumption by the reticuloendothelial system. In the absence of a spleen, these particles circulate for longer periods and facilitate assembly of calcium-dependent coagulation factors that generate thrombin. They also promote an immune response, cell adhesion, inflammation, and vascular remodeling. Higher levels of microparticles correlate with an increased incidence of venous thromboembolism and more severe pulmonary hypertension in a dose-dependent fashion. 18 Most studies report a very long time interval between splenectomy and the development of pulmonary hypertension, which suggests that the process is either very slow or additional factors develop that lead to increased local thrombosis. 
Splenectomy as a consequence of portal hypertension
Splenectomy is typically carried out to alter a patient's clinical course or provide symptomatic relief. 9 There are many indications for splenectomy but the most common is trauma. 10 Other common indications include idiopathic thrombocytopenic purpura, hemolytic anemia, erythrocyte membrane or enzyme disorders, hemoglobinopathies, neoplasms, iatrogenic injuries, symptomaticsplenomegaly/autoinfarction, and hypersplenism. [9] [10] [11] Most cases of hypersplenism are secondary to portal hypertension. 9 Treatment of hypersplenism can be indicated to allow for therapies directed at underlying liver disease, thrombocytopenia with bleeding, and spleen autoinfarction.
11 Treatment options include partial splenic embolization, radiofrequency ablation, splenectomy, and shunt surgeries (side-to-side splenorenal, mesenteric left portal, and proximal splenorenal shunts).
11 Splenectomy relieves the hypersplenism but not the portal hypertension and there is an associated increased risk of cardiovascular events including myocardial infarction, stroke, and pulmonary hypertension as well as splenic or portal vein thrombosis. 9, 11, 12 Advantages of proximal splenorenal shunts are that both the portal hypertension and hypersplenism are relieved as well as improved patient comfort with removal of the often enlarged spleen. 12 Autoimmune disorders causing portal hypertension and pulmonary hypertension Autoimmune hepatitis, PBC, and PSC are three autoimmune hepatobiliary disorders that can ultimately result in portal hypertension, cirrhosis, and decompensated liver failure. The pathogenesis of these conditions is thought to be a combination of environmental stimuli and genetic predisposition that results in an autoimmune response towards various hepatobiliary antigens. This leads to inflammation, fibrosis, and eventually cirrhosis. [23] [24] [25] [26] [27] In the majority of cases, portal hypertension occurs secondary to increased resistance in portal blood flow through a cirrhotic liver and augmented portal inflow from splanchnic vasodilation not adequately compensated by portosystemic collaterals. 26 However, a small percentage of patients with PBC or PSC can actually develop presinusoidal portal hypertension prior to the development of cirrhosis through mechanisms that are not fully understood. [23] [24] [25] [26] [27] After portal hypertension occurs, a small subset of AIH/PBC/PSC patients can develop POPH.
4,28
Limitations
A major strength yet limitation to our study was the sample size. Portopulmonary hypertension is a rare disease, and despite our cohort of 141 patients being one of the largest to date, the actual sample size is small. The number of patients of interest (prior splenectomy) was even smaller. Our study being a retrospective chart review was another limitation. Because POPH is a rare disease and a large number of patients evaluated for this condition received their primary medical care elsewhere, detailed medical records were sometimes limited.
CONCLUSIONS
I N THIS RETROSPECTIVE chart review of patients with POPH, 6% had a history of splenectomy, which is similar to the prevalence found in prior IPAH and CTEPH studies. Autoimmune liver disease (AIH/ PBC/PSC) had a higher frequency than expected (19%) in those with POPH. The only significant difference between POPH subgroups was a higher RVSP measured by TTE in the isolated splenectomy group. There may be a potential opportunity to diagnose and treat this subgroup of patients sooner with earlier TTE screening. Clinicians should therefore consider assessing for a history of splenectomy in patients with portal hypertension, especially in those with autoimmune liver disease who are already at increased risk of developing POPH. The exact mechanisms behind splenectomy and the development of POPH are not fully understood. Further studies are necessary to better understand this relationship.
Key Points
• Increased prevalence of splenectomy (6%) in portopulmonary hypertension population similar to prior idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension studies.
• Higher right ventricle systolic pressure by echocardiography in isolated splenectomy group.
• Potential to diagnose/treat portopulmonary hypertension sooner in splenectomy patients with earlier echocardiography screening.
• Autoimmune liver disease (autoimmune hepatitis/ primary biliary cirrhosis/primary sclerosing cholangitis) had a higher frequency than expected (19%) in those with portopulmonary hypertension.
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